Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VIVACTIL vs ASENDIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.
Amoxapine, a dibenzoxazepine tricyclic antidepressant, primarily inhibits the reuptake of norepinephrine and serotonin. Its metabolite, 7-hydroxyamoxapine, exhibits dopamine D2 receptor antagonism, contributing to its antipsychotic effects.
Major depressive disorder
Treatment of depression (neurotic and psychotic depression),Off-label: anxiety disorders, agitation in schizophrenia
10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.
50 mg orally three times daily, increased gradually to 100-200 mg/day in divided doses. Max 300 mg/day.
Terminal elimination half-life ranges 18–34 hours (mean ~25 hours); clinical steady-state achieved within 5–7 days.
Terminal elimination half-life is approximately 24-30 hours. Clinical context: Steady-state is reached within 5-7 days; the half-life supports once-daily dosing in most patients.
Primarily hepatic via CYP2D6 and other microsomal enzymes; active metabolite desmethylprotriptyline.
Primarily hepatic via CYP450 enzymes, notably CYP2D6 and CYP3A4. Major metabolites: 7-hydroxyamoxapine (active) and 8-hydroxyamoxapine.
Primarily renal (approximately 70% as metabolites, <5% unchanged), with the remainder via fecal/biliary elimination.
Renal (approximately 50% as unchanged drug and metabolites), biliary/fecal (30-40%), with the remainder as other metabolites; <10% excreted unchanged in urine.
Approximately 90% bound, primarily to albumin and α1-acid glycoprotein.
90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Vd approximately 8–15 L/kg, indicating extensive tissue distribution with higher CNS concentration than plasma.
Apparent volume of distribution is 8-10 L/kg, indicating extensive tissue distribution and accumulation in peripheral compartments.
Oral bioavailability approximately 30–40% due to first-pass metabolism (extensive hepatic cytochrome P450 biotransformation).
Oral bioavailability is approximately 70-80% due to first-pass metabolism. No parenteral formulation is available; only oral route.
For GFR <10 m L/min: use with caution and consider 50% dose reduction; no specific guidelines for GFR 10-50 m L/min.
Cr Cl 30-60 m L/min: reduce dose by 25-50%. Cr Cl <30 m L/min: contraindicated.
Child-Pugh class B or C: reduce dose by 50-75%; avoid use in severe hepatic impairment.
Child-Pugh class C: contraindicated. Child-Pugh class B: reduce dose by 50%.
Not recommended for children <12 years; for adolescents 12-18 years: 5-10 mg orally twice daily, max 60 mg/day.
Not recommended for use in children due to lack of safety data.
Initiate at 5 mg orally twice daily; increase slowly with monitoring for orthostatic hypotension and anticholinergic effects.
Initial dose 25 mg twice daily, increase slowly with close monitoring due to increased sensitivity and anticholinergic effects.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Activation of mania/hypomania,Seizure threshold lowering,Cardiovascular toxicity (QT prolongation, arrhythmias),Angle-closure glaucoma,Urinary retention,Hepatic impairment,Concomitant MAOI use
Suicidality risk,Neuroleptic malignant syndrome,Tardive dyskinesia,Seizure threshold lowering,Cardiotoxicity (QT prolongation, arrhythmias),Anticholinergic effects,Hypotension,Hepatic impairment
Hypersensitivity to protriptyline,Recent myocardial infarction,Concurrent MAOI therapy,QT prolongation or concomitant QT-prolonging drugs
Hypersensitivity to amoxapine or any component,Concomitant use with MAOIs or within 14 days of MAOI discontinuation,Acute recovery phase after myocardial infarction,Known alcohol or barbiturate intoxication
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products, soy sauce) if taking with MAOIs; however, protriptyline alone has no significant tyramine interaction. Grapefruit juice may increase protriptyline levels; avoid high intake. Alcohol can potentiate CNS depression. High-fiber foods may slightly reduce absorption; take at same time each day.
Avoid ethanol; may cause additive CNS depression. No specific food interactions; however, taking with food may reduce GI upset.
First trimester: Limited data; possible association with cardiovascular malformations. Second trimester: No specific malformations reported. Third trimester: Risk of neonatal withdrawal, respiratory distress, tachycardia, and hyperirritability if used near term.
ASENDIN (amoxapine) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Risk of congenital malformations cannot be excluded. Second and third trimesters: Neonates may exhibit transient withdrawal symptoms (jitteriness, respiratory depression) or serotonin syndrome if used near term. Avoid use unless benefit outweighs risk.
Present in breast milk; M/P ratio 0.5–1.9. Cases of drowsiness and poor feeding in infants reported; avoid breastfeeding or use with caution.
Amoxapine is excreted in human breast milk. M/P ratio is unknown. Due to limited safety data, breastfeeding is not recommended during therapy. If essential, monitor infant for sedation, poor feeding, and weight loss.
Decreased plasma concentrations due to increased volume of distribution; consider dose adjustment based on clinical response and serum levels; start at low dose and titrate.
No specific dose adjustments are established. Due to increased plasma volume and hepatic metabolism in pregnancy, therapeutic drug monitoring is recommended to ensure efficacy and avoid toxicity. Initiate at low doses and titrate based on clinical response and serum concentrations if available.
VIVACTIL (protriptyline) is a tricyclic antidepressant with a more activating profile; it has the fastest onset of weight gain among TCAs. It is often used for ADHD, narcolepsy, and depression with psychomotor retardation. Due to its long half-life (54-92 hours), dosing should be conservative in elderly. It has a high anticholinergic burden, risking urinary retention and cognitive impairment in older adults. Avoid in patients with recent MI or arrhythmias. Monitor EKG and drug levels in suspected overdose.
Asendin (amoxapine) is a dibenzoxazepine antidepressant with a 7-hydroxy metabolite that confers dopamine blockade, giving it a unique antipsychotic profile. Monitor for extrapyramidal symptoms and tardive dyskinesia, especially in elderly patients. Due to significant anticholinergic effects, use cautiously in patients with benign prostatic hyperplasia, narrow-angle glaucoma, or cognitive impairment. Avoid coadministration with MAOIs; allow at least 14 days between therapies. May cause a false-positive urine amphetamine screen due to structural similarity.
Take exactly as prescribed; do not stop suddenly as withdrawal may occur.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any suicidal thoughts or worsening depression immediately.,May cause dry mouth, constipation, blurred vision; use sugarless candy or gum for dry mouth.,Rise slowly from sitting or lying to prevent dizziness.,Do not take with MAOIs or within 14 days of stopping them.,Notify doctor if you experience fast/irregular heartbeat, difficulty urinating, or seizures.
Take exactly as prescribed; do not stop abruptly or adjust dose without consulting your doctor.,Avoid alcohol and other CNS depressants as they can increase drowsiness and dizziness.,May cause dry mouth; use sugar-free gum or candy to alleviate.,Report any unusual movements, especially of the face or tongue, or severe muscle stiffness.,May increase sensitivity to sunlight; use sunscreen and protective clothing.,Inform all healthcare providers you are taking this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VIVACTIL vs ASENDIN, answered by our medical review team.
VIVACTIL is a Tricyclic Antidepressant that works by Norepinephrine and serotonin reuptake inhibitor; also has anticholinergic and antihistaminergic activity.. ASENDIN is a Tricyclic Antidepressant that works by Amoxapine, a dibenzoxazepine tricyclic antidepressant, primarily inhibits the reuptake of norepinephrine and serotonin. Its metabolite, 7-hydroxyamoxapine, exhibits dopamine D2 receptor antagonism, contributing to its antipsychotic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VIVACTIL and ASENDIN depend on the specific clinical indication. These are both Tricyclic Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VIVACTIL is: 10 mg orally twice daily (morning and afternoon) or 10 mg once daily at bedtime; may increase gradually to 60 mg/day in divided doses.. The standard adult dose of ASENDIN is: 50 mg orally three times daily, increased gradually to 100-200 mg/day in divided doses. Max 300 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VIVACTIL and ASENDIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VIVACTIL is classified as Category C. First trimester: Limited data; possible association with cardiovascular malformations. Second trimester: No specific malformations reported. Third trimester: Risk of neonatal withd. ASENDIN is classified as Category C. ASENDIN (amoxapine) is classified as FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Risk of congenital malformatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.